PARIS/BOSTON (Reuters) – Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially hostile takeover battle.
Performance Optimization WordPress Plugins by W3 EDGE
